Home/Filings/4/0001610717-24-000167
4//SEC Filing

Krause Kevin Michael 4

Accession 0001610717-24-000167

CIK 0001880438other

Filed

Mar 17, 8:00 PM ET

Accepted

Mar 18, 7:28 PM ET

Size

18.2 KB

Accession

0001610717-24-000167

Insider Transaction Report

Form 4
Period: 2024-03-15
Krause Kevin Michael
Chief Strategy Officer
Transactions
  • Award

    Common Stock

    2024-03-15+30,00031,914 total
  • Award

    Stock Option (right to buy)

    2024-03-15+60,00060,000 total
    Exercise: $3.00Exp: 2034-03-14Common Stock (60,000 underlying)
Footnotes (2)
  • [F1]These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
  • [F2]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

Issuer

AN2 Therapeutics, Inc.

CIK 0001880438

Entity typeother

Related Parties

1
  • filerCIK 0001916925

Filing Metadata

Form type
4
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 7:28 PM ET
Size
18.2 KB